Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VBIV Jan 2023 4.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 09:56AM EDT. Market open.
Advertisement
Full screen
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.1000
Strike4.50
Expire Date2023-01-20
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume10
Open Interest375
  • Business Wire

    VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

    CAMBRIDGE, Mass., September 29, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate expressing the full-length spike proteins from the SARS-CoV-1 (SARS), SARS-CoV-2 (COVID-19), and MERS-CoV (MERS) viruses.

  • Business Wire

    VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting

    CAMBRIDGE, Mass., September 21, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

  • Business Wire

    VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

    CAMBRIDGE, Mass., September 15, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

Advertisement
Advertisement